The Washington Times

Ronald Petersen

Latest Ronald Petersen Items
  • Lilly Alzheimer's drug shows some promise in study

    A possible Alzheimer's disease treatment from drugmaker Eli Lilly showed some promise in late-stage research, even though the drug failed to slow a form of mental decline in two separate studies of patients with the mind-robbing condition.


  • Alzheimer's drug fails study but flashes potential

    An Alzheimer's treatment from Eli Lilly and Co. failed to slow memory decline in two separate patient studies, but the drug did show some potential to help in mild cases of the mind-robbing condition that is notoriously difficult to treat.


  • Alzheimer's drug fails in 1 study, 2nd continues

    A closely watched experimental Alzheimer's treatment has failed to slow the disease in one late-stage study, a big disappointment for doctors and patients but not the end of the road for the drug. Pfizer Inc. said Monday that it will continue to study its effect on a different group of patients.


  • Small study: Drug may help stabilize Alzheimer's

    For the first time, researchers are reporting that a treatment might help stabilize Alzheimer's disease for as much as three years, although the evidence is weak and in only four patients.


  • This photo from July 8, 2012, shows Gammagard, a treatment that is being tested for Alzheimer's disease, at the home of a patient in New York. (Associated Press)

    Last drugs standing: Key Alzheimer results coming

    We're about to find out if there will be a way anytime soon to slow the course of Alzheimer's disease. Results are due within a month or so from key studies of two drugs that aim to clear the sticky plaque gumming up patients' brains.


  • Last drugs standing: Key Alzheimer results coming

    We're about to find out if there will be a way anytime soon to slow the course of Alzheimer's disease. Results are due within a month or so from key studies of two drugs that aim to clear the sticky plaque gumming up patients' brains.


  • Aricept helps moderate to severe Alzheimer's too

    Alzheimer's disease patients who are taking a commonly prescribed drug can still benefit from it after they progress to moderate-to-severe illness, when it can be tough to tell whether it's doing any good, a new study says.


  • Families urge action as US drafts Alzheimer's plan

    As her mother's Alzheimer's worsened over eight long years, so did Doreen Alfaro's bills: The walker, then the wheelchair, then the hospital bed, then the diapers _ and the caregivers hired for more and more hours a day so Alfaro could go to work and her elderly father could get some rest.


  • Families urge action as US drafts Alzheimer's plan

    As her mother's Alzheimer's worsened over eight long years, so did Doreen Alfaro's bills: The walker, then the wheelchair, then the hospital bed, then the diapers _ and the caregivers hired for more and more hours a day so Alfaro could go to work and her elderly father could get some rest.


Happening Now